CD14 and relapsing-remitting multiple sclerosis: RRMS patients naive to DMTs showed a higher percentage of Mo-MDSCs than HCs, with ROC curves confirming Mo-MDSCs and inflammatory monocytes, CD14+CD16+ as potential disease biomarkers.